The estimated Net Worth of Elaine Caughey is at least $872 Tausend dollars as of 1 March 2023. Elaine Caughey owns over 714 units of Kymera Therapeutics stock worth over $850,003 and over the last 3 years Elaine sold KYMR stock worth over $22,134.
Elaine has made over 1 trades of the Kymera Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently Elaine sold 714 units of KYMR stock worth $22,134 on 1 March 2023.
The largest trade Elaine's ever made was selling 714 units of Kymera Therapeutics stock on 1 March 2023 worth over $22,134. On average, Elaine trades about 238 units every 0 days since 2021. As of 1 March 2023 Elaine still owns at least 18,986 units of Kymera Therapeutics stock.
You can see the complete history of Elaine Caughey stock trades at the bottom of the page.
Elaine's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at Kymera Therapeutics have traded over $179,227,903 worth of Kymera Therapeutics stock and bought 2,497,406 units worth $70,844,455 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Bros. Advisors Lp667, L.P.B... und Group, Llc Green Jeremy Red.... On average, Kymera Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,989,455. The most recent stock trade was executed by Jeffrey W. Albers on 26 August 2024, trading 5,000 units of KYMR stock currently worth $51,700.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics executives and other stock owners filed with the SEC include: